Phase 4 N=200 CONSORT Randomized Controlled Trial in Assisted Reproductive Technology
Infertility
Primary: Number of Oocytes Retrieved Per Participant — 10.0; 11.8 oocytes — p=0.037
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=76 Early Surgery Versus Conventional Treatment in Infective Endocarditis
Endocarditis
Primary: Number of Participants With In-hospital Death or Clinical Embolic Events — 9; 1 participants — p=<0.05
Phase 4 N=542 Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6. — 73; 132 participants — p=<0.001
Phase 4 N=29 Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Primary: Dupaul ADHD Rating Scale — 31.4; 13.6 units on a scale
Phase 4 N=506 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease
Gastroesophageal Reflux
Primary: Change From Baseline in Reflux Disease Symptom - Heartburn — 59; 117; 186; 7 participants
Phase 4 N=27 Brain Effects of Escitalopram and Citalopram Using fMRI
Antidepressant Activity in Healthy Volunteers
Primary: Number of Voxels Showing Greater Activation Following Escitalopram Compared With Citalopram When Happy and Fearful Faces Are Presented in a Rapid Covert Stimulus…
Phase 4 N=35 Topical Antimicrobial Effectiveness Testing
Antimicrobial Effectiveness
Primary: Antimicrobial Efficacy Will be Measured by the Change (+/-) in Bacterial Count on the Skin 10 Minutes After a Single Application of Test Material Relative to the…
Phase 4 N=43 Topical Antimicrobial Effectiveness Testing
Antimicrobial Effectiveness
Primary: Antimicrobial Efficacy — 2.21; 2.25 log 10 colony forming units / cm^2 — p=< 0.05
Phase 4 N=1,562 Valsartan Intensified Primary Care Reduction of Blood Pressure Study
Hypertension
Primary: Percentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target — 27.4; 33.0…
Phase 4 N=442 Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Peak Expiratory Flow (PEF) 5 Minutes After Morning Dose — 15.1; 13.4 liters/minute
Phase 4 N=111 Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD
Chronic Obstructive Pulmonary Disease
Primary: Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose — 529; 441; 406 Seconds
Phase 4 N=217 POWER (Pulse Width Optimized Waveform Evaluation Trial)
Sudden Cardiac Death
Primary: Defibrillation Thresholds (DFTs) (3.5 ms Waveform) — 427 Volts
Phase 4 N=980 Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT)
Heart Failure
Primary: Left Ventricular End-systolic Volume (LVESV) — -15; -19; -21 ml — p=.66
Phase 4 N=45 A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Renal Plasma Flow (RPF) After a Single Dose of Aliskiren or Irbesartan — 37.18; 35.88 mL/min/1.73m^2
Phase 4 N=260 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms
Parkinsonian Syndromes
Primary: Changes That the Doctor Made in the Clinical Management of Subjects Based Upon the Impact of the Imaging Product. — 33; 28; 19; 11 Number of changes in clinical management